• Anavex disclosed FDA granted a meeting to discuss adding pediatric patients to its Phase 3 Rett syndrome trial of ANAVEX 2-73.
• No clinical results were presented, with the update focused on potential trial expansion rather than study outcomes.
• The move could broaden the addressable patient population, supporting the strategic push behind the Rett syndrome program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001211), on September 09, 2026, and is solely responsible for the information contained therein.